Xeris Biopharma Holdings Dirección

Dirección controles de criterios 2/4

El CEO de Xeris Biopharma Holdings' es Paul Edick , nombrado en May 2021, tiene una permanencia de 2.92 años. compensación anual total es $2.81M, compuesta por 24.7% salario y 75.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.15% de las acciones de la empresa, por valor de €2.85M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 2.5 años, respectivamente.

Información clave

Paul Edick

Chief Executive Officer (CEO)

US$2.1m

Compensación total

Porcentaje del salario del CEO	32.5%
Permanencia del CEO	3yrs
Participación del CEO	0.8%
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	2.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Edick en comparación con los beneficios de Xeris Biopharma Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$64m
Dec 31 2023	US$2m	US$694k	-US$62m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$78m
Dec 31 2022	US$3m	US$692k	-US$95m
Sep 30 2022	n/a	n/a	-US$133m
Jun 30 2022	n/a	n/a	-US$137m
Mar 31 2022	n/a	n/a	-US$138m
Dec 31 2021	US$4m	US$664k	-US$123m
Sep 30 2021	n/a	n/a	-US$94m
Jun 30 2021	n/a	n/a	-US$84m
Mar 31 2021	n/a	n/a	-US$80m
Dec 31 2020	US$2m	US$627k	-US$91m
Sep 30 2020	n/a	n/a	-US$102m
Jun 30 2020	n/a	n/a	-US$119m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$4m	US$598k	-US$126m
Sep 30 2019	n/a	n/a	-US$113m
Jun 30 2019	n/a	n/a	-US$95m
Mar 31 2019	n/a	n/a	-US$73m
Dec 31 2018	US$1m	US$535k	-US$60m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$42m
Mar 31 2018	n/a	n/a	-US$34m
Dec 31 2017	US$1m	US$490k	-US$27m

Compensación vs. Mercado: La compensación total de Paul($USD2.14M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD705.27K).

Compensación vs. Ingresos: La compensación de Paul ha sido consistente con los resultados de la empresa en el último año.

CEO

Paul Edick (67 yo)

3yrs

Permanencia

US$2,136,766

Compensación

Mr. Paul R. Edick serves as the Chief Executive Officer of Xeris Biopharma Holdings, Inc. since May 2021 in connection with the Strongbridge acquisition and has been its Chairman since 2021. He served as P...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Edick	Chairman & CEO	3yrs	US$2.14m	0.78% $ 2.1m
John Shannon	President & COO	2.6yrs	US$1.85m	0.37% $ 1.0m
Steven Pieper	Chief Financial Officer	2.6yrs	US$1.61m	0.26% $ 705.2k
Beth Hecht	Chief Legal Officer & Corporate Secretary	2.6yrs	US$1.13m	0.21% $ 575.9k
Kenneth Johnson	Senior VP of Global Development & Medical Affairs	2.6yrs	US$720.97k	0.071% $ 191.8k
Allison Wey	Senior Vice President of Investor Relations & Corporate Communications	5.8yrs	sin datos	sin datos
Kevin McCulloch	Chief Commercial Officer	no data	sin datos	sin datos

2.6yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2B30 se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Edick	Chairman & CEO	3.3yrs	US$2.14m	0.78% $ 2.1m
John Brooks	Scientific Advisory Board Member	no data	sin datos	sin datos
Orville Kolterman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeffrey Sherman	Independent Director	2.6yrs	US$175.75k	0.052% $ 140.8k
John Schmid	Lead Independent Director	2.6yrs	US$218.25k	0.025% $ 67.5k
Garheng Kong	Independent Non-Executive Director	2.6yrs	US$173.25k	0.048% $ 130.5k
W. Ward	Member of Scientific Advisory Board	no data	sin datos	sin datos
Marla Persky	Independent Director	2.6yrs	US$183.25k	0.014% $ 38.9k
Morey Haymond	Scientific Advisory Board Member	no data	sin datos	sin datos
John Johnson	Independent Non-Executive Director	2.6yrs	US$168.25k	0.54% $ 1.5m
Barbar-Jean Bormann-Kennedy	Independent Director	2.6yrs	US$183.25k	0.010% $ 27.3k
Dawn Halkuff	Independent Director	2.6yrs	US$175.75k	0.014% $ 37.2k

2.6yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de 2B30 no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Xeris Biopharma Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Xeris Biopharma Holdings, Inc., Annual General Meeting, Jun 05, 2024

High number of new and inexperienced directors

Chairman & CEO recently bought €135k worth of stock

Less than half of directors are independent

Chairman & CEO recently bought €363k worth of stock

Less than half of directors are independent

Recent updates

Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.12 loss in 1Q 2023)

Xeris Biopharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

Xeris Biopharma Holdings, Inc., Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: US$0.45 loss per share (vs US$0.70 loss in FY 2022)

Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024

Xeris Biopharma Holdings, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Forecast to breakeven in 2026

Third quarter 2023 earnings released: US$0.088 loss per share (vs US$0.16 loss in 3Q 2022)

Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Full Year 2023

New major risk - Financial position

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.19 loss in 2Q 2022)

Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2023

Xeris Biopharma Holdings, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Xeris Biopharma Holdings, Inc. Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Forecast to breakeven in 2025

Xeris Biopharma Holdings, Inc. Affirms Earnings Guidance for 2023

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$0.70 loss per share (vs US$1.55 loss in FY 2021)

Xeris Biopharma Holdings, Inc. Updates Product Revenue Guidance for the Full Year 2022

Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.39 loss in 3Q 2021)

Xeris Biopharma Holdings, Inc. Provides Product Revenue Guidance for the Full Year 2022

Xeris Biopharma Holdings, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Xeris Biopharma Holdings, Inc. Announces Results of the Extended Evaluation of Recorlev (Levoketoconazole) from the Phase 3 Sonics Study Published in the European Journal of Endocrinology

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.41 loss in 2Q 2021)

Xeris Biopharma Holdings, Inc. Reaffirms Revenue for the Full Year 2022

Xeris Biopharma Holdings, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Arecor Therapeutics plc (AIM:AREC) agreed to acquire Tetris Pharma Limited from Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS).

Chairman & CEO recently bought €135k worth of stock

First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.30 loss in 1Q 2021)

Xeris Announces Full Results from the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data At AACE Annual Meeting May 12-14

Xeris Biopharma Holdings, Inc. Affirms Revenue Guidance for the Year 2022

Xeris Biopharma Holdings, Inc. to Report Q1, 2022 Results on May 11, 2022

Less than half of directors are independent

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Xeris Biopharma Holdings, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Xeris Biopharma Holdings, Inc. Announces Recorlev Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients with Cushing’S Syndrome

Xeris Biopharma Holdings, Inc. announced that it expects to receive $30 million in funding from Armistice Capital LLC

Forecast to breakeven in 2024

Xeris Biopharma Announces U.S. FDA Approval of Recorlev (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

Xeris Biopharma Holdings, Inc Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma

Chairman & CEO recently bought €363k worth of stock

Third quarter 2021 earnings released: US$0.39 loss per share (vs US$0.35 loss in 3Q 2020)

Less than half of directors are independent

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad